Ricerc@Sapienza

Background: Mounting evidence suggests SARS-CoV-2 may impact on host microbiota and gut inflammation, infecting intestinal epithelial cells. This possible link and its implications can be investigated by observing the effects of modulation of the microbial flora in patients with COVID-19. The aim of this study was to compare the rate of mortality, the need of ICU hospitalization and the length of hospitalization in patients with severe COVID-19 pneumonia who received the best available therapy (BAT) vs. patients treated with BAT and supplemented with oral bacteriotherapy.

Background: Mounting evidence suggests SARS-CoV-2 may impact on host microbiota and gut inflammation, infecting intestinal epithelial cells. This possible link and its implications can be investigated by observing the effects of modulation of the microbial flora in patients with COVID-19. The aim of this study was to compare the rate of mortality, the need of ICU hospitalization and the length of hospitalization in patients with severe COVID-19 pneumonia who received the best available therapy (BAT) vs. patients treated with BAT and supplemented with oral bacteriotherapy.

INTRODUCTION The gastrointestinal tract is a major site of HIV localization and even
though cART (combined AntiRetroviral Therapy) leads to suppression of HIV replication
the gastrointestinal pathology is still persistent. In these patients increased levels of inflammation
and decreased levels of mucosal repair and regeneration are observed. Consequently
novel directions for dietary and therapeutic interventions that restore the immunological
and epithelial integrity of the mucosal barrier are needed. Since HIV infected patients host